

acute or chronic rejection in a recipient of organ or tissue xenograft transplant, comprising administering to the patient an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin with an effective amount of a second agent selected from the group consisting of a cyclosporin or an immunosuppressive analog thereof, an ascomycin or immunosuppressive analog thereof, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxysperguatine, immunosuppressive monoclonal antibodies, and CTLA4-Ig.

12. (new) The method of Claim 11 wherein the second agent is cyclosporin A, cyclosporin G, FK-506 or monoclonal antibodies to leukocyte receptors or to their ligands.
13. (new) The method of Claim 11 wherein the second agent is monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58, or to ligands thereof.
14. (new) The method of Claim 13 wherein the second agent is monoclonal antibodies to CD3.
15. (new) The method of Claim 11 wherein the second agent is cyclosporin A.
16. (new) The method of Claim 11 wherein the second agent is cyclosporin G.
17. (new) The method of Claim 11 wherein the second agent is mycophenolic acid.
18. (new) The method of Claim 11 wherein the second agent is CTLA4-Ig.
19. (new) The method of Claim 11 wherein the second agent is mycophenolate mofetil.
20. (new) A method for preventing or treating:
neointimal proliferation and thickening and/or restenosis and/or vascular occlusion following vascular injury,
comprising administering to the patient an effective amount of 40-O-(2-hydroxy)ethyl-rapamycin with an effective amount of a second agent selected from the group consisting of a cyclosporin or an immunosuppressive analog thereof, an ascomycin or immunosuppressive analog thereof, a corticosteroid, cyclophosphamide, azathioprene, methotrexate, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxysperguatine, immunosuppressive monoclonal antibodies, and CTLA4-Ig.


21. (new) The method of Claim 20 wherein the second agent is cyclosporin A, cyclosporin G, FK-506 or monoclonal antibodies to leukocyte receptors or to their ligands.
22. (new) The method of Claim 20 wherein the second agent is monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45, CD58, or to ligands thereof.
23. (new) The method of Claim 22 wherein the second agent is monoclonal antibodies to CD3.
24. (new) The method of Claim 20 wherein the second agent is cyclosporin A.
25. (new) The method of Claim 20 wherein the second agent is cyclosporin G.
26. (new) The method of Claim 20 wherein the second agent is mycophenolic acid.
27. (new) The method of Claim 20 wherein the second agent is CTLA4lg.
28. (new) The method of Claim 20 wherein the second agent is mycophenolate mofetil. --

REMARKS

Favorable consideration of this application is respectfully requested.

Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6765


Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Date: March 7, 2002